BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Medical device company Globus Medical (NYSE:GMED) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

In other recent news, Globus Medical reported its first-quarter 2025 financial results, revealing unexpected shortfalls in both revenue and earnings. The company posted sales of $598.1 million ...

2025 Net Sales Guidance: $2.8 billion to $2.9 billion. 2025 Non-GAAP EPS Guidance: Revised to $3.00 to $3.30. Globus Medical Inc (NYSE:GMED) achieved a significant increase in free cash flow ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million ...

M edical device company Globus Medical (NYSE:GMED) in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 ...

Issues impacting sales included temporary supply chain ... acquisition of Nevro Corporation for $250 million, expanding Globus Medical's reach into the musculoskeletal market, particularly in ...